A Phase 2 interventional study of ABX464 in Ulcerative Colitis, sponsored by Abivax S.A.. Completed at 120 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 239 studies in Colitis, Ulcerative with a site in France — 46 open to participants now, 79 under way, 27 of them phase 3. Colitis, Ulcerative · France.
Among the 239 studies in Colitis, Ulcerative with a site in France, this one is the 80th largest by enrollment of the 184 interventional ones that give a count, is one of 15 that started in 2020, is one of 60 in phase 2, and was the 131st registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →46 of the 239 studies in Colitis, Ulcerative with a site in France are open now. Recruiting first, the newest first:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Palisade Bio · Sites in France, United States, Canada and 9 more countries
Ages 18–75
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 17
Pfizer · Sites in France, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in France, United States, Argentina and 30 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
239 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 71 · Phase 3 73 · Phase 4 14
First in 2003; this study’s year is marked. 15 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 217 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 196 across the 184 interventional studies, 360 across the 55 observational. Of the 150 that completed or were terminated, 71 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
149 of 239 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 8 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
22 of the studies in Colitis, Ulcerative with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 22 to your calendar (.ics) → With an account.
Among the 239 studies in Colitis, Ulcerative with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A phase 2b study to evaluate the long-term efficacy and safety study of ABX464 50mg as maintenance therapy in patients with moderate to severe Ulcerative Colitis.
This study is an open-label study aiming at evaluating the long-term safety and the efficacy profile of ABX464 given once a day (o.d) at 50 mg in subjects who have been previously enrolled in the ABX464-103 clinical study (induction study) and who are willing to continue their treatment. All subjects will receive ABX464 given at 50mg o.d regardless of their previous treatment and dose received in the ABX464-103 study (i.e. ABX464 100mg, ABX464 50mg, ABX464 25mg or Placebo). The enrolment in this follow-up study will be based on the willingness of the subject to carry on his/her participation. Subjects will be treated with ABX464 for an overall period of 48 weeks. Subjects will be followed up on a monthly basis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Criteria that should be met by patients at week 48 to be eligible for 48 additional weeks of study treatment.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
Drug: ABX464
ABX464 All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
Also known as: Obefazimod
Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103)
Clinical remission (based on the Mayo scoring system) is defined as: a rectal bleeding sub-score = 0, and an endoscopy sub-score ≤1 (excluding friability), and at least 1-point decrease in stool frequency sub-score from baseline to achieve a stool frequency sub-score ≤1
Time frame: week 48
Proportion of Patients With Clinical Response at Weeks 48 and 96 Compared to Baseline of Induction Study
Proportion of patients with clinical response at week 48 Clinical response is defined as: a reduction in Mayo Score ≥ 3 points and ≥ 30 % from baseline with an accompanying decrease in rectal bleeding sub-score ≥ 1 point or absolute rectal bleeding sub-score ≤ 1 point.
Time frame: Weeks 48 and 96
Endoscopic Improvement at Weeks 48 and 96
Proportion of patients with endoscopic improvement at week 48 among all patients. Proportion of patients with endoscopic improvement at week 96 among all patients. Endoscopic improvement is defined as a Mayo endoscopic sub score of ≤1 (excluding friability).
Time frame: week 48 and week 96
Endoscopic Remission at Weeks 48 and 96
Proportion of patients with endoscopic remission at week 48 among all patients. Proportion of patients with endoscopic remission at week 96 among all patients. Endoscopic remission is defined as a Mayo endoscopic sub score of 0.
Time frame: week 48 and week 96
Sustained Endoscopic Changes at Week 48 and Week 96
Proportion of patients with sustained endoscopic changes at week 48 and 96. Sustained endoscopic changes is defined as the number of patients with endoscopic changes at week 48 among patients who had endoscopic changes during the Induction study (at week 8 or week 16 of study ABX464-103).
Time frame: weeks 48 and 96
Change in Modified Mayo Score and in Partial Modified Mayo Score
Change in Modified Mayo Score (MMS) at weeks 48 and 96 and in partial Modified Mayo Score (pMMS) MMS is a composite score of UC disease activity calculated as the sum of the following 3 subscores: 1. Stool frequency, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding, scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic evaluation, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease. pMMS is a composite score of UC disease activity calculed as the sum of the following 2 subscores: 1. Stool frequency, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding, scored from 0 (no blood seen) to 3 (blood alone passed). The overall pMMS ranges from 0 to 6 where higher scores represent more severe disease.
Time frame: From baseline to week 96
Stool Frequency Subscore
Participants recorded stool frequency using a paper subject diary on a daily basis. The stool frequency subscore ranges from 0 to 3 according to the following scale: Score 0: Normal number of stools Score 1: 1 to 2 stools per day more than normal Score 2: 3 to 4 stools per day more than normal Score 3: 5 or more stools per day more than normal
Time frame: From baseline to week 96
Rectal Bleeding Score
Participants recorded rectal bleeding in a paper subject diary on a daily basis. Rectal bleeding score is taken as the worst subscore of the three most recent scores within 7 days prior to the visit. The rectal bleeding subscore ranges from 0 to 3 according to the following scale: Score 0: No blood seen Score 1: Streaks of blood with stool less than half the time Score 2: Obvious blood with stool most of the time Score 3: Blood alone passed A lower score represents an improvement in rectal bleeding.
Time frame: From baseline to week 96
C-Reactive Protein
Change to baseline in C-Reactive Protein levels
Time frame: baseline, week 24, week 48
miRNA-124 Expression
Change relative to baseline in miRNA-124 expression in rectal/sigmoidal biopsies at week 48 and in total blood at week 24 and week 48.
Time frame: baseline, week 24 and week 48
Incidence and Description of Adverse Events
Number and rate of all adverse events, causally-related adverse events, all serious adverse events and causally-related serious adverse events classified by severity. Incidence of treatment-emergent serious adverse events, hospitalizations, total inpatient days. Incidence of adverse events leading to investigational product discontinuation. Number of clinically significant laboratory abnormalities.
Time frame: From baseline to week 96
| Milestone | ABX464 50mg |
|---|---|
| Started | 217 |
| Completed | 164 |
| Not completed | 53 |
| Withdrew: Adverse event | 16 |
| Withdrew: Death | 1 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Pregnancy | 4 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Physician decision | 4 |
| Withdrew: Other reason (e.g., ukraine crisis) | 10 |
Clinical remission (based on the Mayo scoring system) is defined as: a rectal bleeding sub-score = 0, and an endoscopy sub-score ≤1 (excluding friability), and at least 1-point decrease in stool frequency sub-score from baseline to achieve a stool frequency sub-score ≤1
| Participants | ABX464 50mg |
|---|---|
| Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103) | 119 |
Proportion of patients with clinical response at week 48 Clinical response is defined as: a reduction in Mayo Score ≥ 3 points and ≥ 30 % from baseline with an accompanying decrease in rectal bleeding sub-score ≥ 1 point or absolute rectal bleeding sub-score ≤ 1 point.
| Participants | ABX464 50mg |
|---|---|
| Week 48 | 177 |
| Week 96 | 158 |
Proportion of patients with endoscopic improvement at week 48 among all patients. Proportion of patients with endoscopic improvement at week 96 among all patients. Endoscopic improvement is defined as a Mayo endoscopic sub score of ≤1 (excluding friability).
| Participants | ABX464 50mg |
|---|---|
| Week 48 | 133 |
| Week 96 | 128 |
Proportion of patients with endoscopic remission at week 48 among all patients. Proportion of patients with endoscopic remission at week 96 among all patients. Endoscopic remission is defined as a Mayo endoscopic sub score of 0.
| Participants | ABX464 50mg |
|---|---|
| Week 48 | 72 |
| Week 96 | 78 |
Proportion of patients with sustained endoscopic changes at week 48 and 96. Sustained endoscopic changes is defined as the number of patients with endoscopic changes at week 48 among patients who had endoscopic changes during the Induction study (at week 8 or week 16 of study ABX464-103).
| Participants | ABX464 50mg |
|---|---|
| Sustained endoscopic improvement at Week 48 | 53 |
| Sustained endoscopic remission at Week 48 | 13 |
| Sustained endoscopic improvement at Week 96 | 50 |
| Sustained endoscopic remission at Week 96 | 11 |
Change in Modified Mayo Score (MMS) at weeks 48 and 96 and in partial Modified Mayo Score (pMMS) MMS is a composite score of UC disease activity calculated as the sum of the following 3 subscores: 1. Stool frequency, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding, scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic evaluation, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease. pMMS is a composite score of UC disease activity calculed as the sum of the following 2 subscores: 1. Stool frequency, scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding, scored from 0 (no blood seen) to 3 (blood alone passed). The overall pMMS ranges from 0 to 6 where higher scores represent more severe disease.
| units on a scale | ABX464 50mg |
|---|---|
| MMS baseline ISB | 7.0 ± 1.07 |
| MMS baseline BOLS | 4.0 ± 2.02 |
| MMS Week 48 | 1.8 ± 1.47 |
| MMS Week 96 | 1.5 ± 1.48 |
| pMMS baseline ISB | 4.2 ± 1.01 |
| pMMS baseline BOLS | 1.8 ± 1.31 |
| pMMS Week 4 | 1.4 ± 1.17 |
| pMMS Week 8 | 1.4 ± 1.24 |
| pMMS Week 12 | 1.3 ± 1.22 |
| pMMS Week 16 | 1.3 ± 1.2 |
| pMMS Week 20 | 1.2 ± 1.14 |
| pMMS Week 24 | 1.1 ± 1.06 |
| pMMS Week 28 | 1.1 ± 1.09 |
| pMMS Week 32 | 1.0 ± 1.00 |
| pMMS Week 36 | 1.0 ± 0.98 |
| pMMS Week 40 | 0.9 ± 0.94 |
| pMMS Week 44 | 0.9 ± 0.98 |
| pMMS Week 48 | 0.8 ± 0.88 |
| pMMS Week 60 | 0.7 ± 0.80 |
| pMMS Week 72 | 0.7 ± 0.84 |
| pMMS Week 84 | 0.7 ± 0.93 |
| pMMS Week 96 | 0.7 ± 0.79 |
Participants recorded stool frequency using a paper subject diary on a daily basis. The stool frequency subscore ranges from 0 to 3 according to the following scale: Score 0: Normal number of stools Score 1: 1 to 2 stools per day more than normal Score 2: 3 to 4 stools per day more than normal Score 3: 5 or more stools per day more than normal
| score on a scale | ABX464 50mg |
|---|---|
| Stool frequency - Baseline ISB | 2.6 ± 0.66 |
| Stool frequency - Baseline BOLS | 1.4 ± 0.94 |
| Stool frequency - Week 4 | 1.2 ± 0.89 |
| Stool frequency - Week 8 | 1.2 ± 0.93 |
| Stool frequency - Week 12 | 1.1 ± 0.93 |
| Stool frequency - Week 16 | 1.1 ± 0.93 |
| Stool frequency - Week 20 | 1.0 ± 0.92 |
| Stool frequency - Week 24 | 1.0 ± 0.83 |
| Stool frequency - Week 28 | 0.9 ± 0.87 |
| Stool frequency - Week 32 | 0.9 ± 0.78 |
| Stool frequency - Week 36 | 0.9 ± 0.82 |
| Stool frequency - Week 40 | 0.8 ± 0.8 |
| Stool frequency - Week 44 | 0.8 ± 0.8 |
| Stool frequency - Week 48 | 0.7 ± 0.79 |
| Stool frequency - Week 60 | 0.7 ± 0.73 |
| Stool frequency - Week 72 | 0.7 ± 0.76 |
| Stool frequency - Week 84 | 0.7 ± 0.77 |
| Stool frequency - Week 96 | 0.6 ± 0.73 |
Participants recorded rectal bleeding in a paper subject diary on a daily basis. Rectal bleeding score is taken as the worst subscore of the three most recent scores within 7 days prior to the visit. The rectal bleeding subscore ranges from 0 to 3 according to the following scale: Score 0: No blood seen Score 1: Streaks of blood with stool less than half the time Score 2: Obvious blood with stool most of the time Score 3: Blood alone passed A lower score represents an improvement in rectal bleeding.
| score on a scale | ABX464 50mg |
|---|---|
| Rectal bleeding Score - Baseline ISB | 1.6 ± 0.72 |
| Rectal bleeding Score - Baseline BOLS | 0.4 ± 0.66 |
| Rectal bleeding Score - Week 4 | 0.2 ± 0.49 |
| Rectal bleeding Score - Week 8 | 0.2 ± 0.56 |
| Rectal bleeding Score - Week 12 | 0.2 ± 0.50 |
| Rectal bleeding Score - Week 16 | 0.2 ± 0.51 |
| Rectal bleeding Score - Week 20 | 0.2 ± 0.49 |
| Rectal bleeding Score - Week 24 | 0.2 ± 0.46 |
| Rectal bleeding Score - Week 28 | 0.1 ± 0.42 |
| Rectal bleeding Score - Week 32 | 0.1 ± 0.39 |
| Rectal bleeding Score - Week 36 | 0.1 ± 0.38 |
| Rectal bleeding Score - Week 40 | 0.1 ± 0.37 |
| Rectal bleeding Score - Week 44 | 0.1 ± 0.37 |
| Rectal bleeding Score - Week 48 | 0.0 ± 0.23 |
| Rectal bleeding Score - Week 60 | 0.0 ± 0.24 |
| Rectal bleeding Score - Week 72 | 0.0 ± 0.24 |
| Rectal bleeding Score - Week 84 | 0.1 ± 0.36 |
| Rectal bleeding Score - Week 96 | 0.0 ± 0.22 |
Change to baseline in C-Reactive Protein levels
| mg/L | ABX464 50mg |
|---|---|
| Baseline BOLS | 6.66 ± 12.17 |
| Week 24 | 5.07 ± 10.43 |
| Week 48 | 5.01 ± 11.31 |
Change relative to baseline in miRNA-124 expression in rectal/sigmoidal biopsies at week 48 and in total blood at week 24 and week 48.
| copy number/cell | ABX464 50mg |
|---|---|
| miR-124 - Rectal - Baseline | 0.00065 ± 0.00211 |
| miR-124 - Rectal - Week 48 | 0.00255 ± 0.00252 |
| miR-124 - Sigmoidal- Baseline | 0.00035 ± 0.00050 |
| miR-124 - Sigmoidal- Week 48 | 0.00225 ± 0.00216 |
| miR-124 - Blood- Baseline | 0.00000 ± 0.00000 |
| miR-124 - Blood- Week 24 | 0.00011 ± 0.00015 |
| miR-124 - Blood- Week 48 | 0.00013 ± 0.00026 |
Number and rate of all adverse events, causally-related adverse events, all serious adverse events and causally-related serious adverse events classified by severity. Incidence of treatment-emergent serious adverse events, hospitalizations, total inpatient days. Incidence of adverse events leading to investigational product discontinuation. Number of clinically significant laboratory abnormalities.
| Participants | ABX464 50mg |
|---|---|
| AEs | 149 |
| TEAEs | 148 |
| Related TEAEs | 54 |
| SAEs | 18 |
| TESAEs | 18 |
| TEAEs leading to discontinuation of investigational product | 26 |
| TEAEs leading to study discontinuation | 17 |
Collected over 96 weeks. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABX464 50mg | 1/217 (0.5%) | 18/217 (8.3%) | 148/217 (68.2%) |
| Event | ABX464 50mg |
|---|---|
| ProctitisGastrointestinal disorders | 2/217 |
| Left ventricular dysfunctionCardiac disorders | 1/217 |
| PalpitationsCardiac disorders | 1/217 |
| Colon dysplasiaGastrointestinal disorders | 1/217 |
| VomitingGastrointestinal disorders | 1/217 |
| ApendicitisInfections and infestations | 1/217 |
| COVID-19Infections and infestations | 1/217 |
| COVID-19 pneunomiaInfections and infestations | 1/217 |
| UrosepsisInfections and infestations | 1/217 |
| InjuryInjury, poisoning and procedural complications | 1/217 |
| Event | ABX464 50mg |
|---|---|
| COVID-19Infections and infestations | 31/217 |
| HeadacheNervous system disorders | 25/217 |
| Colitis ulcerativeGastrointestinal disorders | 17/217 |
| NasopharyngitisInfections and infestations | 15/217 |
| Back painMusculoskeletal and connective tissue disorders | 12/217 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/217 |
| Fecal calprotectin increasedInvestigations | 10/217 |
| Blood cholesterol increasedInvestigations | 8/217 |
| Abdominal painGastrointestinal disorders | 8/217 |
| NauseaGastrointestinal disorders | 8/217 |
Patients with moderate to severe UC who were previously enrolled in the ABX464 103 clinical study (induction study). All patients who completed the 16-week (± 4 days) induction treatment period (ABX464-103) were eligible for this maintenance study regardless of their clinical response. Enrolled patients in ABX464 104 clinical study were willing to continue treatment with ABX464 as long-term (maintenance) therapy of remission.
| Age, Continuous(years) | ABX464 50mg |
|---|---|
| Mean | 42.1 ± 13.77 |
| Sex: Female, Male(Participants) | ABX464 50mg |
|---|---|
| Female | 84 |
| Male | 133 |
| Race and Ethnicity Not Collected(Participants) | ABX464 50mg |
|---|
| Region of Enrollment(participants) | ABX464 50mg |
|---|---|
| Hungary | 17 |
| Czechia | 12 |
| Ukraine | 30 |
| Spain | 1 |
| Canada | 5 |
| Austria | 7 |
| Belgium | 8 |
| Poland | 63 |
| Italy | 17 |
| Slovakia | 16 |
| Slovenia | 3 |
| France | 24 |
| Serbia | 5 |
| Germany | 9 |
Showing the first 100 of 120 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2020 to primary completion in Feb 2023, 37 months.
Results were first posted in Apr 2025, 2 years 2 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 37 months is above that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464